To report a case of acute kidney injury (AKI) associated with polymyxin B in a burn patient and discuss pharmaceutical management strategies, highlighting its implications for clinical practice.
Key Findings:
Polymyxin B can cause acute kidney injury, especially in burn patients, necessitating careful monitoring.
Dose adjustment based on renal function is crucial for patient safety and effective treatment.
Therapeutic drug monitoring is recommended to prevent nephrotoxicity and ensure optimal dosing.
Interpretation:
The case highlights the importance of vigilant monitoring and timely dose adjustments of polymyxin B in patients at risk of AKI, particularly those with extensive burns.
Limitations:
Single case study limits generalizability; findings may not apply to all burn patients.
Lack of long-term follow-up data on renal function post-treatment restricts understanding of long-term outcomes.
Conclusion:
Prompt renal function assessment and dosage modification are essential in managing polymyxin B therapy in burn patients to mitigate the risk of AKI.
